Aclaris Therapeutics ACRS Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's total equity?
- Aclaris Therapeutics (ACRS) reported total equity of $143.65M in Q1 2026.
- How has Aclaris Therapeutics's total equity changed year-over-year?
- Aclaris Therapeutics's total equity decreased by 0.3% year-over-year, from $144.07M to $143.65M.
- What is the long-term trend for Aclaris Therapeutics's total equity?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's total equity has grown at a 22.3% compound annual growth rate (CAGR), from $37.65M to $103.08M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.